End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
Abstract Model‐informed drug development (MIDD) is critical in all stages of the drug‐development process and almost all regulatory submissions for new agents incorporate some form of modeling and simulation. This review describes the MIDD approaches used in the end‐to‐end development of ertuglifloz...
Saved in:
Main Authors: | Daryl J. Fediuk (Author), Gianluca Nucci (Author), Vikas K. Dawra (Author), Ernesto Callegari (Author), Susan Zhou (Author), Cynthia J. Musante (Author), Yali Liang (Author), Kevin Sweeney (Author), Vaishali Sahasrabudhe (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018) -
Physiologically‐Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
by: Ernesto Callegari, et al.
Published: (2021) -
Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers
by: Daryl J. Fediuk, et al.
Published: (2021) -
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022) -
Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018)